Cancer NetworkOriginal article
<![CDATA[Clinical Scenario: Limits of Endocrine Therapy and Closing Remarks]]>
PalbociclibLetrozoleNeutral
AI Analysis
Summary
Dr. Neil Iyengar presents a clinical case of a 61-year-old woman with HER2-low metastatic breast cancer who developed resistance to endocrine therapy after developing ESR1 and PIK3CA mutations, illustrating the limits of standard endocrine treatment approaches.
Importance:2/10
Sentiment:
0.00
breast cancerendocrine therapyHER2-lowESR1 mutationPIK3CA mutationtreatment resistancecase study
Related Companies
Read the original article
Published by Cancer Network on October 6, 2026 2:03 PM